ClinicalTrials.gg
CompletedNCT00531284Updated Aug 15, 2017Results posted

Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma

A Phase 1/2 interventional study of Carfilzomib and Dexamethasone in Ovarian Cancer, Renal Cancer and Non-small Cell Lung Cancer, sponsored by Amgen. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-08-15.

Sponsored by Amgen · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
184
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Ovarian Neoplasms by Amgen — none open to participants now, 1 under way, 1 of them phase 3. Ovarian Neoplasms · Amgen.

Enrollment
6th of 14
184 · median 153
Started
2007
with 1 other
Phase 1/2
Only one
of the 17
Registered
7th of 17
by date

Among the 17 studies in Ovarian Neoplasms by Amgen, this one is the 6th largest by enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2007, is the only one in phase 1/2, and was the 7th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

None of the 17 studies in Ovarian Neoplasms by Amgen is open now. The open studies under Ovarian Neoplasms, anywhere →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies in Ovarian Neoplasms by Amgen as a file.
02

Study summary

The primary objectives of this Phase 1b/2 study were as follows:

  • Phase 1b (Bolus and Infusion): To evaluate the safety and tolerability of carfilzomib in patients with relapsed solid tumors and in patients with relapsed and/or refractory multiple myeloma and in patients with refractory lymphoma.
  • Phase 2 (Bolus): To evaluate the overall response rate (ORR) after 4 cycles of carfilzomib in patients with relapsed solid tumors.
03

Conditions studied

  • Ovarian Cancer
  • Renal Cancer
  • Non-small Cell Lung Cancer
  • Small Cell Lung Cancer
  • Solid Tumors
  • Multiple Myeloma
  • Lymphoma

Keywords

  • Non-small cell lung carcinoma
  • Small-cell lung carcinoma
  • Ovarian Cancer
  • Renal Cancer
  • Other solid tumors
  • multiple myeloma
  • lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Disease related

Phase 1 Subjects (Bolus and Infusion):

Solid Tumor:

  • confirmed advanced solid tumor
  • 1 to 3 prior treatment regimens
  • At least one site of radiographically of ≥ 2 cm in the largest dimension by traditional computed tomography (CT) scanning technique or ≥ 1 cm in the largest dimension by spiral CT scanning (per [RECIST] criteria); or if, in the Principal Investigator's opinion, evaluable disease can be reliably and consistently followed, the subject may be eligible upon approval by the Medical Monitor

Multiple Myeloma (MM):

  • multiple myeloma following 2 or more prior treatment regimens.
  • Measurable disease as indicated by one or more of the following:
  • Serum M-protein ≥ 1 g/dL
  • Urine M-protein ≥ 200 mg/24 hr
  • Serum Free Light Chain: Involved free light chain (FLC) level ≥ 10 mg/dL provided serum FLC ratio is abnormal

Lymphoma:

  • Histologically or cytologically confirmed lymphoma.
  • Patients must have had an initial diagnosis of indolent non-Hodgkin lymphoma (NHL) (including follicular, small lymphocytic, lymphoplasmacytoid, and marginal zone lymphoma), indolent disease that transformed to a more aggressive subtype, as previously described or patients may have mantle cell lymphoma.
  • Patients are required to have received prior rituximab (alone or combined with other treatment) and are considered refractory to (defined as no response, or progression within 6 months of completing therapy) or intolerant of continued rituximab.
  • Patients may have received up to a maximum of four prior unique chemotherapy regimens, including if not stem-cell transplantation (ASCT).
  • For patients to enroll in the expanded dose group for lymphoma, patients must have measurable disease

Phase 2 Bolus Subjects:

-Histologically confirmed advanced solid tumor diagnosis and:

  • Non-small cell lung cancer (NSCLC): Failed at least 1 prior platinum-based chemotherapy regimen but not more than 3 prior therapies for disease
  • Small cell lung cancer (SCLC): Failed 1 to 3 prior chemotherapy regimens
  • Ovarian: Failed at least 1 prior platinum-based chemotherapy regimen but not more than 4 therapies for metastatic disease
  • Renal: Failed at least 2 prior chemotherapy regimens for metastatic disease
  • Other solid tumor types: Failed at least 1 prior chemotherapy regimen for metastatic or relapsed disease and for which standard of care therapy is no longer effective or does not exist
  • At least one site of radiographically measurable disease of ≥ 2 cm in the largest dimension by traditional CT scanning technique or ≥ 1 cm in the largest dimension by spiral CT scanning (per RECIST criteria); or if, in the Principal Investigator's opinion, evaluable disease can be reliably and consistently followed, the subject may be eligible upon approval by the Medical Monitor

Demographic

  • Males and females ≥ 18 years of age
  • of more than 3 months
  • (ECOG) Performance Status 0-2

Laboratory

  • Adequate hepatic function, with 1.5 times the (ULN), and (ALT) 3 times ULN
  • (ANC) > 1000/mm³, ≥ 8 gm/dL for solid tumors or 7.0 gm/dL for MM, and count ≥ 100,000/mm³ for solid tumors or ≥ 30,000/mm³ for MM.

    • Subjects should not have received platelet transfusions for at least 1 week prior to screening
    • Screening ANC should be independent of granulocyte- and granulocyte/macrophage colony stimulating factor (G-CSF and GM-CSF) support for at least 1 week and of pegylated G-CSF for ≥ 2 weeks
    • Subjects may receive red blood cell (RBC) transfusions or receive supportive care with erythropoietin or darbepoetin in accordance with institutional guidelines
  • Calculated or measured (CrCl) of ≥ 20 mL/minute calculated using the formula of Cockcroft and Gault. Subjects with calculated CrCl \< 20 mL/min may be allowed, only with prior approval by the Medical Monitor.

Ethical/Other

  • Written in accordance with federal, local, and institutional guidelines
  • Female subjects of must have a negative serum or urine pregnancy test within 3 days of the first dose and agree to use dual methods of during the study and for 3 months following the last dose of study drug. females (> 45 years old and without menses for > 1 year) and surgically sterilized females are exempt from these requirements. Male subjects must use an effective barrier method of contraception during the study and for 3 months following the last dose if sexually active with a female of childbearing potential.

Exclusion criteria

Exclusion Criteria:

Disease Related

  • Chemotherapy with approved or anticancer therapeutics, including therapy, within 3 weeks prior to first dose or 6 weeks for antibody therapy
  • Radiation therapy or immunotherapy within 3 weeks prior to first dose (except for antibody therapy, where 6 weeks is required); localized radiation therapy within 1 week prior to first dose
  • Subjects with prior are permitted, but must have completed treatment and have no evidence of active central nervous system (CNS) disease for at least 4 weeks prior to first dose
  • For lymphoma patients; patients with prior stem cell transplant therapy ( SCT within the prior 8 weeks; allogeneic SCT within the prior 16 weeks). Patients with prior allogeneic SCT should not have evidence of moderate-to-severe (GVHD)
  • Evidence of CNS lymphoma
  • Participation in an investigational therapeutic study within 3 weeks prior to first dose
  • Prior treatment with carfilzomib

Concurrent Conditions

  • Major surgery within 3 weeks prior to first dose
  • Congestive heart failure ( class III to IV), symptomatic ischemia, conduction abnormalities uncontrolled by conventional intervention, or myocardial infarction within 3 months prior to first dose
  • Acute active infection requiring systemic antibiotics, antivirals, or antifungals within 2 weeks prior to first dose
  • Known or suspected (HIV) infection or subjects who are HIV seropositive
  • Active hepatitis A, B, or C infection
  • Significant neuropathy (Grade 3, Grade 4, or Grade 2 with pain) at the time of the first dose
  • Subjects with pleural effusions requiring routine thoracentesis or ascites requiring routine paracentesis
  • Subjects at risk* in whom the required program of oral and intravenous fluid hydration is , e.g., due to pre-existing pulmonary, cardiac, or renal impairment

    • High risk for Tumor Lysis Syndrome.

Ethical / Other

  • Female subjects who are pregnant or lactating
  • Any psychiatric or medical condition that in the opinion of the Investigator could interfere with protocol adherence or a subject's ability to give
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
184 participants (actual)

Study arms

  • Experimental
    Phase 1B Solid Tumors: Carfilzomib 20 mg/m² Bolus

    Participants received carfilzomib 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.

    Drug: Carfilzomib

  • Experimental
    Phase 1B Solid Tumors: Carfilzomib 20/27 mg/m² Bolus

    Participants received carfilzomib 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Cycle 1 Days 1 and 2 only, then 27 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.

    Drug: Carfilzomib

  • Experimental
    Phase 1B Solid Tumors: Carfilzomib 20/36 mg/m² Bolus

    Participants received carfilzomib 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Cycle 1 Days 1 and 2 only, then 36 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.

    Drug: Carfilzomib

  • Experimental
    Phase 2 Solid Tumors: Carfilzomib 20/36 mg/m² Bolus

    Participants received carfilzomib 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Cycle 1 Days 1 and 2 only, then 36 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.

    Drug: Carfilzomib

  • Experimental
    Phase 1B Solid Tumors: Carfilzomib 36 mg/m²

    Participants received carfilzomib 36 mg/m² administered by intravenous infusion over 30 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for at least 2 cycles. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.

    Drug: Carfilzomib

  • Experimental
    Phase 1B Solid Tumors: Carfilzomib 45 mg/m²

    Participants received carfilzomib 45 mg/m² administered by intravenous infusion over 30 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for at least 2 cycles. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.

    Drug: Carfilzomib

  • Experimental
    Phase 1B Solid Tumors: Carfilzomib 20/45 mg/m²

    Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 45 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.

    Drug: Carfilzomib

  • Experimental
    Phase 1B Solid Tumors: Carfilzomib 20/56 mg/m²

    Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 56 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.

    Drug: Carfilzomib

  • Experimental
    Phase 1B Solid Tumors: Carfilzomib 20/70 mg/m²

    Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 70 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.

    Drug: Carfilzomib

  • Experimental
    Phase 1b Multiple Myeloma: Carfilzomib 20/36 mg/m²

    Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 36 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.

    Drug: Carfilzomib

  • Experimental
    Phase 1b Multiple Myeloma: Carfilzomib 20/45 mg/m²

    Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 45 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.

    Drug: Carfilzomib

  • Experimental
    Phase 1b Multiple Myeloma: Carfilzomib 20/56 mg/m²

    Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 56 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.

    Drug: Carfilzomib

  • Experimental
    Phase 1b Multiple Myeloma: Carfilzomib 20/70 mg/m²

    Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 70 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.

    Drug: Carfilzomib

  • Experimental
    Phase 1b Lymphoma: Carfilzomib 20/56 mg/m²

    Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 56 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.

    Drug: Carfilzomib

  • Experimental
    Phase 1b Lymphoma: Carfilzomib 20/70 mg/m²

    Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 70 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.

    Drug: Carfilzomib

  • Experimental
    Phase 1b MM: Carfilzomib 20/45 mg/m² + Dexamethasone

    Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 45 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment plus dexamethasone 40 mg weekly. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.

    Drug: Carfilzomib · Drug: Dexamethasone

  • Experimental
    Phase 1b MM: Carfilzomib 20/56 mg/m² + Dexamethasone

    Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 56 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment plus dexamethasone 40 mg weekly. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.

    Drug: Carfilzomib · Drug: Dexamethasone

Interventions

  • Administered by intravenous (IV) bolus (2-10 minute) infusion or 30 minute infusion

    Also known as: Kyprolis

  • Administered orally or by IV infusion prior to carfilzomib

06

What researchers measure

Primary outcomes

  1. Phase 1b: Number of Participants With Dose-limiting Toxicities (DLT)

    Participants were evaluated for dose-limiting toxicities according to the Common Terminology Criteria for Adverse Events (CTCAE) of the National Cancer Institute (NCI) version 3.0. A DLT was defined as treatment-related ≥ Grade 2 neuropathy with pain, ≥ Grade 3 non-hematologic toxicity, Grade 4 neutropenia or thrombocytopenia lasting 7 or more days, or thrombocytopenia with bleeding. The maximum tolerated dose (MTD) for each of the 3 populations (solid tumor, multiple myeloma, and lymphoma) was defined as the dose level at which \< 33% of participants experienced a dose-limiting toxicity during the first 28-day cycle.

    Time frame: 28 days

  2. Phase 2: Percentage of Participants With an Overall Response After 4 Treatment Cycles

    Overall response is defined as participants with a best overall response of complete response (CR), partial response (PR) or stable disease (SD) after 4 cycles, assessed by the Investigator using tumor measurement and according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. CR: Disappearance of all target and non-target lesions and no new lesions; PR: Disappearance of all target lesions, persistence of one or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits and no lesions, or, at least a 30% decrease in the size of target lesions and no progression of existing non-target lesions or any new lesions. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest size since the treatment started, and no progression of existing non-target lesions or any new lesions.

    Time frame: 4 months

Secondary outcomes

  1. Percentage of Participants With an Overall Response Throughout the Study

    Solid tumor participants were evaluated for disease response according to RECIST, Version 1.1. Multiple myeloma participants were evaluated using the International Myeloma Working Group (IMWG) Uniform Response Criteria with the addition of minimal response (MR) based on the European Group for Blood and Marrow Transplant Group (EBMT). Non-Hodgkin lymphoma (NHL) participants were evaluated using the International Workshop NHL criteria. Waldenström macroglobulinemia (WM) participants were evaluated using Criteria from the Sixth International Workshop for WM. Overall response is defined in Outcome Measure 2 for participants with solid tumors. For NHL, overall response is defined as a best overall response of CR or PR. For multiple myeloma and WM, overall response is defined as participants with a best overall response of stringent complete response (sCR), CR, very good partial response (VGPR) or PR.

    Time frame: Tumor assessments occurred at the end of Cycle 2, 4, 6, 9, and 12 and continued every 3 cycles thereafter up to 6 months after last dose. Analysis includes data up to the data cut-off date of 07 October 2014; maximum duration of treatment was 35 months.

  2. Duration of Response

    Duration of response is defined as the time from first evidence of a partial response or better (the first observation of PR before confirmation) to disease progression, with deaths owing to causes other than progression censored.

    Time frame: Tumor assessments occurred at the end of Cycle 2, 4, 6, 9, and 12 and continued every 3 cycles thereafter up to 6 months after last dose. Analysis includes data up to the data cut-off date of 07 October 2014; maximum duration of treatment was 35 months.

  3. Progression-Free Survival

    Progression-free survival (PFS) is the time from start of treatment to disease progression or death (due to any cause), whichever occurred first.

    Time frame: Tumor assessments occurred at the end of Cycle 2, 4, 6, 9, and 12 and continued every 3 cycles thereafter up to 6 months after last dose. Analysis includes data up to the data cut-off date of 07 October 2014; maximum duration of treatment was 35 months.

  4. Time to Progression

    Time to Progression (TTP) is defined as number of months between start of treatment and first evidence/documentation of disease progression.

    Time frame: Tumor assessments occurred at the end of Cycle 2, 4, 6, 9, and 12 and continued every 3 cycles thereafter up to 6 months after last dose. Analysis includes data up to the data cut-off date of 07 October 2014; maximum duration of treatment was 35 months.

  5. Maximum Observed Plasma Concentration of Carfilzomib

    Plasma concentrations of carfilzomib were determined by a validated liquid chromatography tandem mass spectrometry method. Concentration values that were below the lower limit of quantification of 0.1 ng/mL were set to zero. Treatment groups receiving the same dose (e.g. 20 mg/m²) were combined for Day 1 analyses.

    Time frame: Cycle 1, Day 1, predose and at 5 minutes and 15 minutes post start of infusion (for 30-minute infusion groups only), and at the end of infusion, 5, 15, and 30 minutes; and 1, 2, and 4 hours after the end of the infusion.

  6. Time to Maximum Observed Plasma Concentration (Tmax) of Carfilzomib

    Time frame: Cycle 1, Day 1, predose and at 5 minutes and 15 minutes post start of infusion (for 30-minute infusion groups only), and at the end of infusion, 5, 15, and 30 minutes; and 1, 2, and 4 hours after the end of the infusion.

  7. Area Under the Plasma Concentration-time Curve From Time Zero to the Last Concentration Measured (AUC0-last) for Carfilzomib

    Time frame: Cycle 1, Day 1, predose and at 5 minutes and 15 minutes post start of infusion (for 30-minute infusion groups only), and at the end of infusion, 5, 15, and 30 minutes; and 1, 2, and 4 hours after the end of the infusion.

  8. Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) for Carfilzomib

    Time frame: Cycle 1, Day 1, predose and at 5 minutes and 15 minutes post start of infusion (for 30-minute infusion groups only), and at the end of infusion, 5, 15, and 30 minutes; and 1, 2, and 4 hours after the end of the infusion.

  9. Elimination Half-life (t½) of Carfilzomib

    Time frame: Cycle 1, Day 1, predose and at 5 minutes and 15 minutes post start of infusion (for 30-minute infusion groups only), and at the end of infusion, 5, 15, and 30 minutes; and 1, 2, and 4 hours after the end of the infusion.

  10. Clearance (CL) of Carfilzomib

    Time frame: Cycle 1, Day 1, predose and at 5 minutes and 15 minutes post start of infusion (for 30-minute infusion groups only), and at the end of infusion, 5, 15, and 30 minutes; and 1, 2, and 4 hours after the end of the infusion.

  11. Volume of Distribution at Steady State (Vss) of Carfilzomib

    Time frame: Cycle 1, Day 1, predose and at 5 minutes and 15 minutes post start of infusion (for 30-minute infusion groups only), and at the end of infusion, 5, 15, and 30 minutes; and 1, 2, and 4 hours after the end of the infusion.

  12. Mean Residence Time (MRT) Extrapolated to Infinity for Carfilzomib

    Time frame: Cycle 1, Day 1, predose and at 5 minutes and 15 minutes post start of infusion (for 30-minute infusion groups only), and at the end of infusion, 5, 15, and 30 minutes; and 1, 2, and 4 hours after the end of the infusion.

07

Results

Posted Dec 9, 2015

Participant flow

Patients with relapsed solid tumors (non-small and small cell lung, ovarian, renal, any other solid tumor type), multiple myeloma or lymphoma were enrolled at 7 sites in the US. Under the original protocol patients received a bolus intravenous (IV) infusion of carfilzomib; patients enrolled under Amendments 2 to 4 received a 30-minute IV infusion.

Participant flow — Overall Study
MilestoneP1B ST: CFZ 20 mg/m² BolusP1B ST: CFZ 20/27 mg/m² BolusP1B ST: CFZ 20/36 mg/m² BolusP2 ST: CFZ 20/36 mg/m² BolusP1B ST: CFZ 36 mg/m²P1B ST: CFZ 45 mg/m²P1B ST: CFZ 20/45 mg/m²P1B ST: CFZ 20/56 mg/m²P1B ST: CFZ 20/70 mg/m²P1B MM: CFZ 20/36 mg/m²P1B MM: CFZ 20/45 mg/m²P1b MM: CFZ 20/56 mg/m²P1B MM: CFZ 20/70 mg/m²P1B LYM: CFZ 20/56 mg/m²P1B LYM: CFZ 20/70 mg/m²P1B MM: CFZ 20/45 mg/m² + DexP1B MM: CFZ 20/56 mg/m² + Dex
Started3476567610114324237148
Completed00120000000000320
Not completed3466367610114324234128
Withdrew: Progressive disease13542443863314212115
Withdrew: Adverse event01170232300501102
Withdrew: Withdrawal by subject10040000000301011
Withdrew: Other100102100210200100

Outcome measures

PrimaryPhase 1b: Number of Participants With Dose-limiting Toxicities (DLT)

Participants were evaluated for dose-limiting toxicities according to the Common Terminology Criteria for Adverse Events (CTCAE) of the National Cancer Institute (NCI) version 3.0. A DLT was defined as treatment-related ≥ Grade 2 neuropathy with pain, ≥ Grade 3 non-hematologic toxicity, Grade 4 neutropenia or thrombocytopenia lasting 7 or more days, or thrombocytopenia with bleeding. The maximum tolerated dose (MTD) for each of the 3 populations (solid tumor, multiple myeloma, and lymphoma) was defined as the dose level at which \< 33% of participants experienced a dose-limiting toxicity during the first 28-day cycle.

Time frame:
28 days
Reported as:
Number · participants
Phase 1b: Number of Participants With Dose-limiting Toxicities (DLT)
participantsP1B ST: CFZ 20 mg/m² BolusP1B ST: CFZ 20/27 mg/m² BolusP1B ST: CFZ 20/36 mg/m² BolusP1B ST: CFZ 36 mg/m²P1B ST: CFZ 45 mg/m²P1B ST: CFZ 20/45 mg/m²P1B ST: CFZ 20/56 mg/m²P1B ST: CFZ 20/70 mg/m²P1B MM: CFZ 20/36 mg/m²P1B MM: CFZ 20/45 mg/m²P1b MM: CFZ 20/56 mg/m²P1B MM: CFZ 20/70 mg/m²P1B LYM: CFZ 20/56 mg/m²P1B LYM: CFZ 20/70 mg/m²
Phase 1b: Number of Participants With Dose-limiting Toxicities (DLT)00102001001201
PrimaryPhase 2: Percentage of Participants With an Overall Response After 4 Treatment Cycles

Overall response is defined as participants with a best overall response of complete response (CR), partial response (PR) or stable disease (SD) after 4 cycles, assessed by the Investigator using tumor measurement and according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. CR: Disappearance of all target and non-target lesions and no new lesions; PR: Disappearance of all target lesions, persistence of one or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits and no lesions, or, at least a 30% decrease in the size of target lesions and no progression of existing non-target lesions or any new lesions. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest size since the treatment started, and no progression of existing non-target lesions or any new lesions.

Time frame:
4 months
Reported as:
Number · percentage of participants
Phase 2: Percentage of Participants With an Overall Response After 4 Treatment Cycles
percentage of participantsP2 ST: CFZ 20/36 mg/m² Bolus
Phase 2: Percentage of Participants With an Overall Response After 4 Treatment Cycles15.4 (7.6 to 26.5)
SecondaryPercentage of Participants With an Overall Response Throughout the Study

Solid tumor participants were evaluated for disease response according to RECIST, Version 1.1. Multiple myeloma participants were evaluated using the International Myeloma Working Group (IMWG) Uniform Response Criteria with the addition of minimal response (MR) based on the European Group for Blood and Marrow Transplant Group (EBMT). Non-Hodgkin lymphoma (NHL) participants were evaluated using the International Workshop NHL criteria. Waldenström macroglobulinemia (WM) participants were evaluated using Criteria from the Sixth International Workshop for WM. Overall response is defined in Outcome Measure 2 for participants with solid tumors. For NHL, overall response is defined as a best overall response of CR or PR. For multiple myeloma and WM, overall response is defined as participants with a best overall response of stringent complete response (sCR), CR, very good partial response (VGPR) or PR.

Time frame:
Tumor assessments occurred at the end of Cycle 2, 4, 6, 9, and 12 and continued every 3 cycles thereafter up to 6 months after last dose. Analysis includes data up to the data cut-off date of 07 October 2014; maximum duration of treatment was 35 months.
Reported as:
Number · percentage of participants
Percentage of Participants With an Overall Response Throughout the Study
percentage of participantsP1B ST: CFZ 20 mg/m² BolusP1B ST: CFZ 20/27 mg/m² BolusP1B ST: CFZ 20/36 mg/m² BolusP2 ST: CFZ 20/36 mg/m² BolusP1B ST: CFZ 36 mg/m²P1B ST: CFZ 45 mg/m²P1B ST: CFZ 20/45 mg/m²P1B ST: CFZ 20/56 mg/m²P1B ST: CFZ 20/70 mg/m²P1B MM: CFZ 20/36 mg/m²P1B MM: CFZ 20/45 mg/m²P1b MM: CFZ 20/56 mg/m²P1B MM: CFZ 20/70 mg/m²P1B NHL: CFZ 20/56 mg/m²P1B NHL: CFZ 20/70 mg/m²P1B WM: CFZ 20/56 mg/m²P1B WM: CFZ 20/70 mg/m²P1B MM: CFZ 20/45 mg/m² + DexP1B MM: CFZ 20/56 mg/m² + Dex
Percentage of Participants With an Overall Response Throughout the Study100.0 (29.2 to 100.0)0.0 (0.0 to 60.2)42.9 (9.9 to 81.6)38.5 (26.7 to 51.4)33.3 (4.3 to 77.7)28.6 (3.7 to 71.0)50.0 (11.8 to 88.2)10.0 (0.3 to 44.5)36.4 (10.9 to 69.2)50.0 (6.8 to 93.2)33.3 (0.8 to 90.6)50.0 (29.1 to 70.9)50.0 (1.3 to 98.7)0.0 (0.0 to 0.0)0.0 (0.0 to 0.0)100.0 (2.5 to 100.0)100.0 (39.8 to 100.0)64.3 (35.1 to 87.2)37.5 (8.5 to 75.5)
SecondaryDuration of Response

Duration of response is defined as the time from first evidence of a partial response or better (the first observation of PR before confirmation) to disease progression, with deaths owing to causes other than progression censored.

Time frame:
Tumor assessments occurred at the end of Cycle 2, 4, 6, 9, and 12 and continued every 3 cycles thereafter up to 6 months after last dose. Analysis includes data up to the data cut-off date of 07 October 2014; maximum duration of treatment was 35 months.
Reported as:
Median · months
Duration of Response
monthsP1B ST: CFZ 20 mg/m² BolusP1B ST: CFZ 20/27 mg/m² BolusP1B ST: CFZ 20/36 mg/m² BolusP2 ST: CFZ 20/36 mg/m² BolusP1B ST: CFZ 36 mg/m²P1B ST: CFZ 45 mg/m²P1B ST: CFZ 20/45 mg/m²P1B ST: CFZ 20/56 mg/m²P1B ST: CFZ 20/70 mg/m²P1B MM: CFZ 20/36 mg/m²P1B MM: CFZ 20/45 mg/m²P1b MM: CFZ 20/56 mg/m²P1B MM: CFZ 20/70 mg/m²P1B NHL: CFZ 20/56 mg/m²P1B NHL: CFZ 20/70 mg/m²P1B WM: CFZ 20/56 mg/m²P1B WM: CFZ 20/70 mg/m²P1B MM: CFZ 20/45 mg/m² + DexP1B MM: CFZ 20/56 mg/m² + Dex
Duration of Response——6.2 (NA to NA)——————9.3 (3.9 to 14.7)5.5 (NA to NA)8.0 (4.1 to 32.5)14.8 (NA to NA)——NA (NA to NA)NA (NA to NA)9.0 (1.9 to NA)22.6 (17.5 to 27.6)
SecondaryProgression-Free Survival

Progression-free survival (PFS) is the time from start of treatment to disease progression or death (due to any cause), whichever occurred first.

Time frame:
Tumor assessments occurred at the end of Cycle 2, 4, 6, 9, and 12 and continued every 3 cycles thereafter up to 6 months after last dose. Analysis includes data up to the data cut-off date of 07 October 2014; maximum duration of treatment was 35 months.
Reported as:
Median · months
Progression-Free Survival
monthsP1B ST: CFZ 20 mg/m² BolusP1B ST: CFZ 20/27 mg/m² BolusP1B ST: CFZ 20/36 mg/m² BolusP2 ST: CFZ 20/36 mg/m² BolusP1B ST: CFZ 36 mg/m²P1B ST: CFZ 45 mg/m²P1B ST: CFZ 20/45 mg/m²P1B ST: CFZ 20/56 mg/m²P1B ST: CFZ 20/70 mg/m²P1B MM: CFZ 20/36 mg/m²P1B MM: CFZ 20/45 mg/m²P1b MM: CFZ 20/56 mg/m²P1B MM: CFZ 20/70 mg/m²P1B NHL: CFZ 20/56 mg/m²P1B NHL: CFZ 20/70 mg/m²P1B WM: CFZ 20/56 mg/m²P1B WM: CFZ 20/70 mg/m²P1B MM: CFZ 20/45 mg/m² + DexP1B MM: CFZ 20/56 mg/m² + Dex
Progression-Free Survival5.1 (NA to NA)1.8 (1.6 to 1.9)1.8 (1.0 to NA)1.8 (1.7 to 2.1)1.7 (1.1 to NA)2.9 (0.9 to 15.4)1.4 (0.3 to 24.6)1.5 (0.3 to 2.0)1.6 (0.4 to 5.4)5.2 (4.4 to 15.1)4.6 (1.4 to 5.9)6.9 (1.2 to 8.4)9.4 (1.9 to 16.8)NA (1.6 to NA)1.0 (0.6 to NA)NA (NA to NA)NA (NA to NA)4.6 (1.9 to 12.7)11.5 (1.8 to 28.0)
SecondaryTime to Progression

Time to Progression (TTP) is defined as number of months between start of treatment and first evidence/documentation of disease progression.

Time frame:
Tumor assessments occurred at the end of Cycle 2, 4, 6, 9, and 12 and continued every 3 cycles thereafter up to 6 months after last dose. Analysis includes data up to the data cut-off date of 07 October 2014; maximum duration of treatment was 35 months.
Reported as:
Median · months
Time to Progression
monthsP1B ST: CFZ 20 mg/m² BolusP1B ST: CFZ 20/27 mg/m² BolusP1B ST: CFZ 20/36 mg/m² BolusP2 ST: CFZ 20/36 mg/m² BolusP1B ST: CFZ 36 mg/m²P1B ST: CFZ 45 mg/m²P1B ST: CFZ 20/45 mg/m²P1B ST: CFZ 20/56 mg/m²P1B ST: CFZ 20/70 mg/m²P1B MM: CFZ 20/36 mg/m²P1B MM: CFZ 20/45 mg/m²P1b MM: CFZ 20/56 mg/m²P1B MM: CFZ 20/70 mg/m²P1B NHL: CFZ 20/56 mg/m²P1B NHL: CFZ 20/70 mg/m²P1B WM: CFZ 20/56 mg/m²P1B WM: CFZ 20/70 mg/m²P1B MM: CFZ 20/45 mg/m² + DexP1B MM: CFZ 20/56 mg/m² + Dex
Time to Progression5.1 (NA to NA)1.8 (1.6 to 1.9)1.8 (1.6 to NA)1.8 (1.7 to 2.1)1.7 (1.1 to NA)1.6 (0.9 to 4.1)1.6 (1.1 to NA)1.6 (0.5 to 2.0)1.6 (0.3 to 5.6)5.2 (4.4 to 15.1)4.6 (1.4 to 5.9)6.9 (1.2 to 8.4)9.4 (1.9 to 16.8)NA (1.6 to NA)1.0 (0.6 to NA)NA (NA to NA)NA (NA to NA)4.6 (1.9 to 12.7)11.5 (1.8 to 28.0)
SecondaryMaximum Observed Plasma Concentration of Carfilzomib

Plasma concentrations of carfilzomib were determined by a validated liquid chromatography tandem mass spectrometry method. Concentration values that were below the lower limit of quantification of 0.1 ng/mL were set to zero. Treatment groups receiving the same dose (e.g. 20 mg/m²) were combined for Day 1 analyses.

Time frame:
Cycle 1, Day 1, predose and at 5 minutes and 15 minutes post start of infusion (for 30-minute infusion groups only), and at the end of infusion, 5, 15, and 30 minutes; and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration of Carfilzomib
ng/mLST: CFZ 20 mg/m² BolusST: CFZ 20 mg/m²ST: CFZ 36 mg/m²ST: CFZ 45 mg/m²MM: CFZ 20 mg/m²
Maximum Observed Plasma Concentration of Carfilzomib2390 ± 104914 ± 58.21061 ± 50.71193 ± 197.3722 ± 62.1
SecondaryTime to Maximum Observed Plasma Concentration (Tmax) of Carfilzomib
Time frame:
Cycle 1, Day 1, predose and at 5 minutes and 15 minutes post start of infusion (for 30-minute infusion groups only), and at the end of infusion, 5, 15, and 30 minutes; and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Median · hours
Time to Maximum Observed Plasma Concentration (Tmax) of Carfilzomib
hoursST: CFZ 20 mg/m² BolusST: CFZ 20 mg/m²ST: CFZ 36 mg/m²ST: CFZ 45 mg/m²MM: CFZ 20 mg/m²
Time to Maximum Observed Plasma Concentration (Tmax) of Carfilzomib0.0500 (0 to 0.167)0.500 (0.0833 to 0.7500)0.258 (0.0833 to 0.500)0.275 (0.100 to 0.550)0.250 (0.0833 to 0.750)
SecondaryArea Under the Plasma Concentration-time Curve From Time Zero to the Last Concentration Measured (AUC0-last) for Carfilzomib
Time frame:
Cycle 1, Day 1, predose and at 5 minutes and 15 minutes post start of infusion (for 30-minute infusion groups only), and at the end of infusion, 5, 15, and 30 minutes; and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Geometric mean · h*ng/mL
Area Under the Plasma Concentration-time Curve From Time Zero to the Last Concentration Measured (AUC0-last) for Carfilzomib
h*ng/mLST: CFZ 20 mg/m² BolusST: CFZ 20 mg/m²ST: CFZ 36 mg/m²ST: CFZ 45 mg/m²MM: CFZ 20 mg/m²
Area Under the Plasma Concentration-time Curve From Time Zero to the Last Concentration Measured (AUC0-last) for Carfilzomib251 ± 92.0346 ± 57.4426 ± 70.1536 ± 150.4269 ± 54.3
SecondaryArea Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) for Carfilzomib
Time frame:
Cycle 1, Day 1, predose and at 5 minutes and 15 minutes post start of infusion (for 30-minute infusion groups only), and at the end of infusion, 5, 15, and 30 minutes; and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Geometric mean · h*ng/mL
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) for Carfilzomib
h*ng/mLST: CFZ 20 mg/m² BolusST: CFZ 20 mg/m²ST: CFZ 36 mg/m²ST: CFZ 45 mg/m²MM: CFZ 20 mg/m²
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) for Carfilzomib223 ± 104324 ± 52.8426 ± 70.1538 ± 150.1273 ± 55.3
SecondaryElimination Half-life (t½) of Carfilzomib
Time frame:
Cycle 1, Day 1, predose and at 5 minutes and 15 minutes post start of infusion (for 30-minute infusion groups only), and at the end of infusion, 5, 15, and 30 minutes; and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Median · hours
Elimination Half-life (t½) of Carfilzomib
hoursST: CFZ 20 mg/m² BolusST: CFZ 20 mg/m²ST: CFZ 36 mg/m²ST: CFZ 45 mg/m²MM: CFZ 20 mg/m²
Elimination Half-life (t½) of Carfilzomib0.444 (0.152 to 2.20)0.888 (0.368 to 2.33)0.917 (0.359 to 1.23)0.952 (0.810 to 2.11)0.888 (0.411 to 1.57)
SecondaryClearance (CL) of Carfilzomib
Time frame:
Cycle 1, Day 1, predose and at 5 minutes and 15 minutes post start of infusion (for 30-minute infusion groups only), and at the end of infusion, 5, 15, and 30 minutes; and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Mean · liters/hour
Clearance (CL) of Carfilzomib
liters/hourST: CFZ 20 mg/m² BolusST: CFZ 20 mg/m²ST: CFZ 36 mg/m²ST: CFZ 45 mg/m²MM: CFZ 20 mg/m²
Clearance (CL) of Carfilzomib263 ± 398139 ± 70.1182 ± 88.8302 ± 438164 ± 89.6
SecondaryVolume of Distribution at Steady State (Vss) of Carfilzomib
Time frame:
Cycle 1, Day 1, predose and at 5 minutes and 15 minutes post start of infusion (for 30-minute infusion groups only), and at the end of infusion, 5, 15, and 30 minutes; and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Mean · liters
Volume of Distribution at Steady State (Vss) of Carfilzomib
litersST: CFZ 20 mg/m² BolusST: CFZ 20 mg/m²ST: CFZ 36 mg/m²ST: CFZ 45 mg/m²MM: CFZ 20 mg/m²
Volume of Distribution at Steady State (Vss) of Carfilzomib27.7 ± 48.631.0 ± 21.922.7 ± 24.2113 ± 23021.8 ± 24.6
SecondaryMean Residence Time (MRT) Extrapolated to Infinity for Carfilzomib
Time frame:
Cycle 1, Day 1, predose and at 5 minutes and 15 minutes post start of infusion (for 30-minute infusion groups only), and at the end of infusion, 5, 15, and 30 minutes; and 1, 2, and 4 hours after the end of the infusion.
Reported as:
Mean · hours
Mean Residence Time (MRT) Extrapolated to Infinity for Carfilzomib
hoursST: CFZ 20 mg/m² BolusST: CFZ 20 mg/m²ST: CFZ 36 mg/m²ST: CFZ 45 mg/m²MM: CFZ 20 mg/m²
Mean Residence Time (MRT) Extrapolated to Infinity for Carfilzomib0.0902 ± 0.03190.227 ± 0.1500.116 ± 0.08280.205 ± 0.1560.117 ± 0.0799

Adverse events

Collected over From the first administration of carfilzomib and within 30 days after the last dose of study treatment; maximum duration of treatment was 366 days for bolus administration and 1073 days for infusion. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
P1B ST: CFZ 20 mg/m² Bolus—1/3 (33.3%)3/3 (100%)
P1B ST: CFZ 20/27 mg/m² Bolus—1/4 (25%)4/4 (100%)
P1B ST: CFZ 20/36 mg/m² Bolus—4/7 (57.1%)7/7 (100%)
P2 ST: CFZ 20/36 mg/m² Bolus—27/65 (41.5%)65/65 (100%)
P1B ST: CFZ 36 mg/m²—2/6 (33.3%)6/6 (100%)
P1B ST: CFZ 45 mg/m²—4/7 (57.1%)7/7 (100%)
P1B ST: CFZ 20/45 mg/m²—5/6 (83.3%)6/6 (100%)
P1B ST: CFZ 20/56 mg/m²—5/10 (50%)10/10 (100%)
P1B ST: CFZ 20/70 mg/m²—6/11 (54.5%)11/11 (100%)
P1B MM: CFZ 20/36 mg/m²—2/4 (50%)4/4 (100%)
P1B MM: CFZ 20/45 mg/m²—0/3 (0%)3/3 (100%)
P1B MM: CFZ 20/56 mg/m²—11/24 (45.8%)24/24 (100%)
P1B MM: CFZ 20/70 mg/m²—2/2 (100%)2/2 (100%)
P1B LYM: CFZ 20/56 mg/m²—1/3 (33.3%)3/3 (100%)
P1B LYM: CFZ 20/70 mg/m²—5/7 (71.4%)7/7 (100%)
P1B MM: CFZ 20/45 mg/m² + Dex—5/14 (35.7%)14/14 (100%)
P1B MM: CFZ 20/56 mg/m² + Dex—3/8 (37.5%)8/8 (100%)
Most frequent serious events
Showing 10 of 76
Most frequent serious events
EventP1B ST: CFZ 20 mg/m² BolusP1B ST: CFZ 20/27 mg/m² BolusP1B ST: CFZ 20/36 mg/m² BolusP2 ST: CFZ 20/36 mg/m² BolusP1B ST: CFZ 36 mg/m²P1B ST: CFZ 45 mg/m²P1B ST: CFZ 20/45 mg/m²P1B ST: CFZ 20/56 mg/m²P1B ST: CFZ 20/70 mg/m²P1B MM: CFZ 20/36 mg/m²P1B MM: CFZ 20/45 mg/m²P1B MM: CFZ 20/56 mg/m²P1B MM: CFZ 20/70 mg/m²P1B LYM: CFZ 20/56 mg/m²P1B LYM: CFZ 20/70 mg/m²P1B MM: CFZ 20/45 mg/m² + DexP1B MM: CFZ 20/56 mg/m² + Dex
ProteinuriaRenal and urinary disorders0/30/40/70/650/60/70/60/100/110/40/30/241/20/30/70/140/8
Renal tubular necrosisRenal and urinary disorders0/30/40/70/650/60/70/60/100/110/40/30/241/20/30/70/140/8
Respiratory distressRespiratory, thoracic and mediastinal disorders0/30/40/70/650/60/70/60/100/110/40/30/241/20/30/70/140/8
Disease progressionGeneral disorders0/30/40/75/650/60/72/61/104/110/40/32/240/20/30/70/140/8
PainGeneral disorders1/30/40/72/650/60/70/60/101/110/40/30/240/20/30/70/140/8
DyspnoeaRespiratory, thoracic and mediastinal disorders0/30/40/71/650/61/71/60/100/110/40/30/240/21/32/70/140/8
Coronary artery diseaseCardiac disorders0/30/40/70/650/60/70/60/100/111/40/30/240/20/30/70/140/8
PyrexiaGeneral disorders0/30/40/71/650/60/70/60/101/111/40/33/240/20/30/70/140/8
Pneumonia aspirationRespiratory, thoracic and mediastinal disorders0/31/40/70/650/60/70/60/101/110/40/30/240/20/30/70/140/8
Back painMusculoskeletal and connective tissue disorders0/30/40/70/650/60/70/62/100/110/40/30/240/20/30/70/140/8
Most frequent other events
Showing 10 of 326
Most frequent other events
EventP1B ST: CFZ 20 mg/m² BolusP1B ST: CFZ 20/27 mg/m² BolusP1B ST: CFZ 20/36 mg/m² BolusP2 ST: CFZ 20/36 mg/m² BolusP1B ST: CFZ 36 mg/m²P1B ST: CFZ 45 mg/m²P1B ST: CFZ 20/45 mg/m²P1B ST: CFZ 20/56 mg/m²P1B ST: CFZ 20/70 mg/m²P1B MM: CFZ 20/36 mg/m²P1B MM: CFZ 20/45 mg/m²P1B MM: CFZ 20/56 mg/m²P1B MM: CFZ 20/70 mg/m²P1B LYM: CFZ 20/56 mg/m²P1B LYM: CFZ 20/70 mg/m²P1B MM: CFZ 20/45 mg/m² + DexP1B MM: CFZ 20/56 mg/m² + Dex
ThrombocytopeniaBlood and lymphatic system disorders0/31/41/71/650/61/70/61/103/111/41/313/242/21/33/75/143/8
FatigueGeneral disorders0/32/43/738/650/64/73/64/105/113/43/314/242/22/33/79/145/8
PyrexiaGeneral disorders0/30/43/717/651/61/72/65/102/111/41/313/241/23/35/72/144/8
NauseaGastrointestinal disorders0/30/44/728/652/64/72/64/106/113/42/313/241/21/31/74/143/8
AstheniaGeneral disorders0/30/44/77/650/61/72/60/100/110/40/32/240/22/31/71/142/8
ChillsGeneral disorders0/30/42/718/651/61/73/62/102/111/42/38/240/20/34/70/141/8
Blood creatinine increasedInvestigations0/30/41/711/650/63/71/63/102/110/42/36/240/20/34/71/140/8
Decreased appetiteMetabolism and nutrition disorders0/30/40/70/650/60/70/61/101/110/40/31/240/22/31/71/140/8
HypomagnesaemiaMetabolism and nutrition disorders2/30/40/74/650/60/70/60/100/110/40/31/240/20/30/70/141/8
Cancer painNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/31/40/72/651/61/71/60/100/110/42/33/240/20/30/70/140/8

Baseline characteristics

Age, Continuous
Age, Continuous(years)P1B ST: CFZ 20 mg/m² BolusP1B ST: CFZ 20/27 mg/m² BolusP1B ST: CFZ 20/36 mg/m² BolusP2 ST: CFZ 20/36 mg/m² BolusP1B ST: CFZ 36 mg/m²P1B ST: CFZ 45 mg/m²P1B ST: CFZ 20/45 mg/m²P1B ST: CFZ 20/56 mg/m²P1B ST: CFZ 20/70 mg/m²P1B MM: CFZ 20/36 mg/m²P1B MM: CFZ 20/45 mg/m²P1b MM: CFZ 20/56 mg/m²P1B MM: CFZ 20/70 mg/m²P1B LYM: CFZ 20/56 mg/m²P1B LYM: CFZ 20/70 mg/m²P1B MM: CFZ 20/45 mg/m² + DexP1B MM: CFZ 20/56 mg/m² + DexTotal
Bolus Groups47.3 ± 14.7460.8 ± 8.8160.0 ± 11.7262.0 ± 9.97NA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA62.20 ± 10.43
30-minute Infusion GroupsNA ± NANA ± NANA ± NANA ± NA60.0 ± 5.1869.9 ± 11.1061.2 ± 10.3861.4 ± 7.4061.6 ± 11.5863.3 ± 3.7772.0 ± 5.5762.7 ± 9.8869.5 ± 12.0258.7 ± 10.6965.4 ± 10.3158.6 ± 9.5458.3 ± 6.1462.3 ± 9.47
Sex: Female, Male
Sex: Female, Male(Participants)P1B ST: CFZ 20 mg/m² BolusP1B ST: CFZ 20/27 mg/m² BolusP1B ST: CFZ 20/36 mg/m² BolusP2 ST: CFZ 20/36 mg/m² BolusP1B ST: CFZ 36 mg/m²P1B ST: CFZ 45 mg/m²P1B ST: CFZ 20/45 mg/m²P1B ST: CFZ 20/56 mg/m²P1B ST: CFZ 20/70 mg/m²P1B MM: CFZ 20/36 mg/m²P1B MM: CFZ 20/45 mg/m²P1b MM: CFZ 20/56 mg/m²P1B MM: CFZ 20/70 mg/m²P1B LYM: CFZ 20/56 mg/m²P1B LYM: CFZ 20/70 mg/m²P1B MM: CFZ 20/45 mg/m² + DexP1B MM: CFZ 20/56 mg/m² + DexTotal
Female11438043542171134180
Male23327633572217124107104
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(participants)P1B ST: CFZ 20 mg/m² BolusP1B ST: CFZ 20/27 mg/m² BolusP1B ST: CFZ 20/36 mg/m² BolusP2 ST: CFZ 20/36 mg/m² BolusP1B ST: CFZ 36 mg/m²P1B ST: CFZ 45 mg/m²P1B ST: CFZ 20/45 mg/m²P1B ST: CFZ 20/56 mg/m²P1B ST: CFZ 20/70 mg/m²P1B MM: CFZ 20/36 mg/m²P1B MM: CFZ 20/45 mg/m²P1b MM: CFZ 20/56 mg/m²P1B MM: CFZ 20/70 mg/m²P1B LYM: CFZ 20/56 mg/m²P1B LYM: CFZ 20/70 mg/m²P1B MM: CFZ 20/45 mg/m² + DexP1B MM: CFZ 20/56 mg/m² + DexTotal
013427210244080237573
1213354467702151036399
2000002010011111109
Missing000300000000000003
08

Study locations

7 sites
  • Pinnacle Oncology
    Scottsdale, Arizona 85258, United States
  • Tower Cancer Research Foundation
    Beverly Hills, California 90210, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • University of Maryland Greenebaum Cancer Center
    Baltimore, Maryland 21201, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • The Sarah Cannon Research Institute
    Nashville, Tennessee 37203-1632, United States
  • South Texas Accelerated Research Therapeutics (START)
    San Antonio, Texas 78229, United States
09

References and documents

Publications

  • Papadopoulos KP, Siegel DS, Vesole DH, Lee P, Rosen ST, Zojwalla N, Holahan JR, Lee S, Wang Z, Badros A. Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma. J Clin Oncol. 2015 Mar 1;33(7):732-9. doi: 10.1200/JCO.2013.52.3522. Epub 2014 Sep 15. PubMed 25225420 ↗
  • Ohshima-Hosoyama S, Davare MA, Hosoyama T, Nelon LD, Keller C. Bortezomib stabilizes NOXA and triggers ROS-associated apoptosis in medulloblastoma. J Neurooncol. 2011 Dec;105(3):475-83. doi: 10.1007/s11060-011-0619-0. Epub 2011 Jun 3. PubMed 21633906 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2007, a primary completion of Oct 2014 and a completion of May 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2015, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2007
First posted
Sep 18, 2007
Start
Sep 2007
Primary completionActual
Oct 2014
CompletionActual
May 22, 2017
Results first posted
Dec 9, 2015
Last update
Aug 15, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00531284
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Sep 18, 2007
Start date
Sep 2007
Primary completion
Oct 2014
Completion
May 22, 2017
Results posted
Dec 9, 2015
Last update
Aug 15, 2017

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Carfilzomib

Start the discussion